Cannock

Researchers are evaluating the safety and tolerability of increasing doses of GSK3862995B. This study involves healthy participants receiving a single dose and participants with Chronic Obstructive Pulmonary Disease (COPD) receiving repeated doses to assess the drug's effects. The trial is a Phase 1, randomized, double-blind, placebo-controlled study designed to also investigate immunogenicity, pharmacokinetics, and pharmacodynamics of GSK3862995B. Participants are divided into two parts: Part A includes healthy volunteers aged 18 to 65 years who receive single ascending doses of GSK3862995B or placebo. Part B includes participants with COPD aged 40 to 75 years who receive repeated doses of the study drug or placebo. Dosing schedules and exact administration details are monitored closely throughout the study. During the study, participants undergo medical evaluations including laboratory tests, vital sign monitoring, cardiac assessments with 12-lead ECG, and recording of adverse events for up to 36 weeks in Part A and 48 weeks in Part B. Researchers will track changes in laboratory values, vital signs, and ECG parameters, as well as collect information on any adverse or serious adverse events. The study includes thorough safety monitoring to understand the tolerability of GSK3862995B over the study period.

Researchers are evaluating the effects of two different default dialysate sodium concentrations, 137 mmol/l and 140 mmol/l, on major cardiovascular events and death in adults receiving maintenance haemodialysis. This pragmatic, cluster-randomised, open-label study takes place in real-world dialysis sites and aims to compare the outcomes associated with these sodium levels over an extended period. The study focuses on patients with end-stage kidney disease undergoing regular haemodialysis treatment. Dialysis sites are randomly assigned to use either a default dialysate sodium concentration of 137 mmol/l or 140 mmol/l for at least 90% of dialysis sessions at that site. All other care practices continue as usual based on local standards. The study plans to recruit sites over 5 to 7 years, with individual follow-up lasting roughly 2 to 5 years. Site participation requires consent, while individual patient consent may be waived or offered an opt-out option. Participants will be monitored for major cardiovascular events and death, with the primary outcome measuring the time until the first such event occurs. Data collection methods are implemented across participating dialysis units, focusing only on in-center or satellite dialysis patients where applicable. The study's duration depends on the occurrence of endpoints, with an average follow-up of about 5 years anticipated per participant.